Quantcast
Last updated on April 21, 2014 at 7:45 EDT

Latest Percutaneous coronary intervention Stories

2013-03-10 12:20:23

Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent NATICK, Mass., March 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System to the Cobalt Chromium (CoCr) Xience V® Everolimus-Eluting Coronary...

2013-03-07 12:27:38

- Health Canada Medical Device Class III license covers broad applications in cardiovascular disease, including for patients undergoing cardiothoracic surgery, interventional cardiothoracic procedures, or patients who have evolving myocardial infarction - TORONTO, March 7, 2013 /PRNewswire/ -- CellAegis Devices, Inc. announced today that it has received marketing authorization from Health Canada that allows for the commercial introduction in Canada of the Company's autoRIC(TM)...

2013-02-27 08:28:34

-- Phase II, randomized, placebo-controlled, multi-center study will measure the primary efficacy endpoint of reduction in ventricular remodeling post-percutaneous coronary intervention (PCI) -- TORONTO, Feb. 27, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC(TM) Device for Chronic Remote Ischemic...

2013-02-19 04:22:57

ALBANY, New York, February 19, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for...

2013-01-31 08:27:02

TORONTO, Jan. 31, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European interventional cardiology market will barely grow through 2017. Procedure growth will average around one percent per year, while revenue growth will be less than that. The market will be just over $1 billion by 2017. There will be a few bright spots of growth, including bioresorbable stents and intravascular imaging....

2013-01-29 09:56:58

More PCI centers are treating more heart attack patients faster, national audit finds The 2011 annual report of the National Audit of Percutaneous Coronary Intervention (PCI) highlights the significant progress within hospitals to expand PCI services to treat more patients with acute coronary syndromes. PCI mechanically improves blood flow to the heart and can be used to relieve the symptoms of angina, prevent and treat heart attacks. When used to treat heart attack patients, the...

2013-01-08 16:23:20

Major breakthrough at DMC Cardiovascular Institute will revolutionize treatment for heart patients with coronary blood-flow disorders, says CVI President Theodore L. Schreiber, M.D. DETROIT, Jan. 8, 2013 /PRNewswire-USNewswire/ -- The Detroit Medical Center (DMC) announced today that a team of heart specialists at its Cardiovascular Institute (CVI) has successfully conducted the Midwest's first-ever "robotic-assisted" coronary revascularization to relieve heart artery...

2013-01-08 08:30:08

TORONTO, Jan. 8, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, declines in procedure volumes in the United States interventional cardiology (IC) market will lead to a long-term contraction. As a result of the procedure volume decline, coupled with increasing cost sensitivity, this market will show a steady contraction from a value of just under $2.5 billion in 2012 to just under $2 billion by 2017. The only...

2013-01-02 16:22:31

NEW YORK, Jan. 2, 2013 /PRNewswire/ -- The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD live longer, and are less likely to suffer a non-fatal heart attack, when treated with bypass surgery instead of drug-eluting stents (DES), tiny, medicine-coated mesh tubes that prop open clogged arteries. The findings were presented in the 2012 American Heart...

2012-12-19 08:25:55

BASKING RIDGE, N.J., Dec. 19, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced it has secured a landmark $51 million Series E financing. The round was led by new investor RusnanoMedInvest, a subsidiary of the state-run Russian investment firm RUSNANO, and included participation from another new, US-based investor, Baxter Healthcare's venture initiative, Baxter Ventures. Existing...


Latest Percutaneous coronary intervention Reference Libraries

Coronary Angiography
2013-07-29 11:05:01

A coronary angiography, also known as a coronary catheterization, is a procedure that gives both visual and tactical access to coronary circulation and blood filled chambers of the heart for both diagnostic and interventional purposes. It is one of many diagnostic tests used in cardiology. More specifically, coronary catheterization recognizes occlusion, stenosis, thrombosis or aneurismal enlargement of the walls of the coronary arteries; heart chamber size; heart muscle contraction...

More Articles (1 articles) »